BRAF mutations not only significantly influence the effects of anti–epidermal growth factor receptor monoclonal antibody treatment but are also closely associated with tumor invasiveness and metastasis, making them crucial indicators for evaluating disease progression and treatment prognosis [79]. This evidence concerns the gene BRAF and neoplasm.